India · Delayed Price · Currency is INR Kabra Drugs Statistics
Total Valuation
Kabra Drugs has a market cap or net worth of INR 602.89 million. The enterprise value is 502.32 million.
| Market Cap | 602.89M |
| Enterprise Value | 502.32M |
Important Dates
The last earnings date was Friday, May 29, 2026.
| Earnings Date | May 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Kabra Drugs has 23.71 million shares outstanding. The number of shares has increased by 117.16% in one year.
| Current Share Class | 23.71M |
| Shares Outstanding | 23.71M |
| Shares Change (YoY) | +117.16% |
| Shares Change (QoQ) | -0.57% |
| Owned by Insiders (%) | 18.09% |
| Owned by Institutions (%) | n/a |
| Float | 19.42M |
Valuation Ratios
The trailing PE ratio is 12.17.
| PE Ratio | 12.17 |
| Forward PE | n/a |
| PS Ratio | 0.65 |
| PB Ratio | 2.04 |
| P/TBV Ratio | 2.04 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 10.13 |
| EV / Sales | 0.54 |
| EV / EBITDA | 9.43 |
| EV / EBIT | 9.55 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.48, with a Debt / Equity ratio of 0.02.
| Current Ratio | 1.48 |
| Quick Ratio | 1.44 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | 0.11 |
| Debt / FCF | -0.06 |
| Interest Coverage | 175.27 |
Financial Efficiency
Return on equity (ROE) is 18.28% and return on invested capital (ROIC) is 26.57%.
| Return on Equity (ROE) | 18.28% |
| Return on Assets (ROA) | 5.89% |
| Return on Invested Capital (ROIC) | 26.57% |
| Return on Capital Employed (ROCE) | 17.69% |
| Weighted Average Cost of Capital (WACC) | 3.72% |
| Revenue Per Employee | 29.92M |
| Profits Per Employee | 1.60M |
| Employee Count | 31 |
| Asset Turnover | 1.66 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Kabra Drugs has paid 7.61 million in taxes.
| Income Tax | 7.61M |
| Effective Tax Rate | 13.30% |
Stock Price Statistics
The stock price has increased by +113.76% in the last 52 weeks. The beta is -0.10, so Kabra Drugs's price volatility has been lower than the market average.
| Beta (5Y) | -0.10 |
| 52-Week Price Change | +113.76% |
| 50-Day Moving Average | 25.25 |
| 200-Day Moving Average | 25.23 |
| Relative Strength Index (RSI) | 58.97 |
| Average Volume (20 Days) | 115,233 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Kabra Drugs had revenue of INR 927.40 million and earned 49.60 million in profits. Earnings per share was 2.09.
| Revenue | 927.40M |
| Gross Profit | 90.76M |
| Operating Income | 52.58M |
| Pretax Income | 57.21M |
| Net Income | 49.60M |
| EBITDA | 52.95M |
| EBIT | 52.58M |
| Earnings Per Share (EPS) | 2.09 |
Balance Sheet
The company has 106.26 million in cash and 5.69 million in debt, with a net cash position of 100.57 million or 4.24 per share.
| Cash & Cash Equivalents | 106.26M |
| Total Debt | 5.69M |
| Net Cash | 100.57M |
| Net Cash Per Share | 4.24 |
| Equity (Book Value) | 296.14M |
| Book Value Per Share | 12.53 |
| Working Capital | 273.84M |
Cash Flow
In the last 12 months, operating cash flow was -94.74 million and capital expenditures -7.02 million, giving a free cash flow of -101.76 million.
| Operating Cash Flow | -94.74M |
| Capital Expenditures | -7.02M |
| Depreciation & Amortization | 370,000 |
| Net Borrowing | 1.15M |
| Free Cash Flow | -101.76M |
| FCF Per Share | -4.29 |
Margins
Gross margin is 9.79%, with operating and profit margins of 5.67% and 5.35%.
| Gross Margin | 9.79% |
| Operating Margin | 5.67% |
| Pretax Margin | 6.17% |
| Profit Margin | 5.35% |
| EBITDA Margin | 5.71% |
| EBIT Margin | 5.67% |
| FCF Margin | n/a |
Dividends & Yields
Kabra Drugs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -117.16% |
| Shareholder Yield | -117.16% |
| Earnings Yield | 8.23% |
| FCF Yield | -16.88% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Kabra Drugs has an Altman Z-Score of 2.33 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.33 |
| Piotroski F-Score | 2 |